These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8703689)

  • 1. PET scanning said to save money and improve staging of lung cancer.
    Oncology (Williston Park); 1995 Nov; 9(11):1200. PubMed ID: 8703689
    [No Abstract]   [Full Text] [Related]  

  • 2. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
    Giaccone G
    J Natl Cancer Inst; 2007 Dec; 99(23):1741-3. PubMed ID: 18042929
    [No Abstract]   [Full Text] [Related]  

  • 3. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Makler PT
    J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic staging of lung cancer.
    Berlangieri SU; Scott AM
    N Engl J Med; 2000 Jul; 343(4):290-2. PubMed ID: 10911013
    [No Abstract]   [Full Text] [Related]  

  • 5. Staging of non-small-cell lung cancer with positron-emission tomography.
    Donckier JE; Roelants V; Pochet JM
    N Engl J Med; 2000 Nov; 343(21):1572; author reply 1572-3. PubMed ID: 11184751
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
    Ung YC; Maziak DE; Vanderveen JA; Smith CA; Gulenchyn K; Lacchetti C; Evans WK;
    J Natl Cancer Inst; 2007 Dec; 99(23):1753-67. PubMed ID: 18042932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
    Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
    Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET in lung cancer staging.
    Coleman RE
    Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PET Scan in the work-up of NSCLC].
    Fornito MC
    Suppl Tumori; 2004; 3(2):S21-4. PubMed ID: 15067959
    [No Abstract]   [Full Text] [Related]  

  • 12. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.
    Bury T; Dowlati A; Paulus P; Hustinx R; Radermecker M; Rigo P
    Eur J Nucl Med; 1996 Feb; 23(2):204-6. PubMed ID: 8925857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging of non-small-cell lung cancer with positron-emission tomography.
    Rosell R
    N Engl J Med; 2000 Nov; 343(21):1572; author reply 1572-3. PubMed ID: 11184750
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography.
    Scott WJ; Gobar LS; Hauser LG; Sunderland JJ; Dewan NA; Sugimoto JT
    Chest; 1995 Apr; 107(4):1174-6. PubMed ID: 7705136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis of early cancer with positron emission tomography].
    Kubota K
    Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
    Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
    Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.
    Groheux D; Quere G; Blanc E; Lemarignier C; Vercellino L; de Margerie-Mellon C; Merlet P; Querellou S
    Diagn Interv Imaging; 2016 Oct; 97(10):1003-1017. PubMed ID: 27567555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].
    Kubota K; Yamada S; Fukuda H; Tanida T; Saitou Y; Takahashi J; Yamada K
    Kaku Igaku; 1997 May; 34(5):329-36. PubMed ID: 9248260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
    Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
    Laking G; Price P
    Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.